Physician profile
Fernando Bueso
NPI 1437108966
$3,370.99
in general payments reported to CMS, 2019-2025
28 companies · $313 in 2025
The $313 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $516 · 2020: $561 · 2021: $374 · 2022: $862 · 2023: $365 · 2024: $381 · 2025: $313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,059.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,058.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $854.25 | 2019-2025 | |
| Novo Nordisk INC | $393.52 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Daiichi Sankyo INC. | $311.16 | 2019-2022 | |
| Currax Pharmaceuticals LLC | $283.02 | 2020-2024 | Contrave |
| Abbott Laboratories | $195.36 | 2022 | |
| Lupin INC. | $153.28 | 2019-2021 | |
| Lilly USA, LLC | $147.09 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $135.09 | 2020-2024 | |
| Exact Sciences Corporation | $109.94 | 2024-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $108.48 | 2023-2025 | Veozah, Myrbetriq |
| Amgen INC. | $73.59 | 2019-2024 | Prolia, Evenity |
| Merck Sharp & Dohme LLC | $66.31 | 2020-2022 | |
| Caldera Medical, INC | $63.43 | 2023 | Desara |
| Merz North America, INC. | $57.54 | 2024 | |
| Allergan, INC. | $53.37 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $46.37 | 2019-2020 | |
| Organon LLC | $43.51 | 2022 | |
| Aspira Women'S Health INC | $39.80 | 2020 | |
| Boston Scientific Corporation | $39.41 | 2023 | |
| Hologic Sales and Service, LLC | $36.69 | 2019-2023 | Thinprep 2000 Processor |
| Janssen Pharmaceuticals, INC | $32.47 | 2023 | Spravato |
| Scynexis, INC. | $20.39 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.20 | 2020 | |
| Conmed Corporation | $19.07 | 2019 | |
| Millicent US INC | $18.33 | 2023 | Intrarosa |
| Kowa Pharmaceuticals America, INC. | $18.09 | 2022 | |
| Duchesnay USA Incorporated | $17.73 | 2019 | |
| Madrigal Pharmaceuticals | $14.50 | 2025 | Rezdiffra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fernando Bueso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.